Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Durvalumab in Recurrent Prostate Cancer
NCT03810105Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2019
- Primary completion
- Jul 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and durvalumab in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Therapeutic Efficacy as Defined by Number of Participants With an Undetectable PSA at 1 year. Started Mar 2019; status: terminated.
02
Drugs
olaparibdurvalumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03810105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810105.